SRPT
Sarepta Therapeutics, Inc. NASDAQ Listed Jun 4, 1997$20.79
Mkt Cap $2.2B
52w Low $10.42
30.8% of range
52w High $44.14
50d MA $19.76
200d MA $19.79
P/E (TTM)
-3.0x
EV/EBITDA
-3.8x
P/B
2.0x
Debt/Equity
0.9x
ROE
-36.1%
P/FCF
-7.3x
RSI (14)
—
ATR (14)
—
Beta
0.28
50d MA
$19.76
200d MA
$19.79
Avg Volume
2.8M
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
215 First Street · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | 0.98 | 3.16 | +223.8% | 23.03 | -3.3% | -9.7% | — | — | — | — | — |
| Feb 25, 2026 | AMC | -1.03 | -3.58 | -247.6% | 18.97 | -6.2% | -8.0% | -4.0% | -2.6% | -2.8% | +1.4% | — |
| Nov 3, 2025 | AMC | 0.01 | -0.13 | -1400.0% | 24.45 | -37.7% | -33.7% | +15.2% | -5.5% | -0.1% | -2.0% | — |
| Aug 6, 2025 | AMC | 0.83 | 2.02 | +142.8% | 16.26 | +12.2% | +10.5% | +1.5% | -1.6% | +4.8% | +8.5% | — |
| May 6, 2025 | AMC | 0.35 | -3.42 | -1077.1% | 46.75 | -14.5% | -21.5% | -0.5% | -0.7% | +0.3% | -0.5% | — |
| Feb 26, 2025 | AMC | 1.38 | 1.50 | +8.7% | 106.86 | -5.5% | -3.6% | +3.6% | -5.2% | +1.6% | +4.7% | — |
| Nov 6, 2024 | AMC | -0.06 | 0.62 | +1139.7% | 127.97 | +3.5% | -5.9% | +1.0% | -3.1% | -3.0% | -1.6% | — |
| Aug 7, 2024 | AMC | 0.01 | 0.07 | +1200.7% | 140.06 | -3.6% | -2.6% | -8.1% | +2.6% | +3.7% | -0.3% | — |
| May 1, 2024 | AMC | 0.10 | 0.73 | +625.6% | 130.90 | +7.0% | -0.2% | +2.3% | +1.0% | +0.7% | -2.5% | — |
| Feb 28, 2024 | AMC | 0.01 | 0.47 | +3084.0% | 137.50 | -0.6% | -7.0% | +0.6% | -3.7% | -0.8% | -2.1% | — |
| Nov 1, 2023 | AMC | -1.66 | -0.46 | +72.3% | 76.52 | +3.8% | +1.6% | +0.3% | +2.7% | +3.5% | -2.7% | — |
| Aug 2, 2023 | AMC | -1.89 | -0.27 | +85.7% | 105.19 | +2.7% | +2.1% | -1.9% | -2.7% | +0.6% | +0.3% | — |
| May 2, 2023 | AMC | -1.46 | -0.97 | +33.6% | 123.69 | -2.6% | +1.4% | +3.8% | +0.6% | -3.2% | -1.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16 | HC Wainwright & Co. | Maintains | Sell → Sell | — | $21.73 | $21.75 | +0.1% | -2.6% | +1.8% | -0.6% | -3.5% | -0.2% |
| Mar 26 | Citigroup | Maintains | Sell → Sell | — | $23.77 | $23.15 | -2.6% | -8.8% | -7.9% | +2.6% | +6.3% | +1.7% |
| Mar 26 | Needham | Maintains | Underperform → Underperform | — | $23.77 | $23.15 | -2.6% | -8.8% | -7.9% | +2.6% | +6.3% | +1.7% |
| Mar 19 | Oppenheimer | Maintains | Outperform → Outperform | — | $17.16 | $16.94 | -1.3% | -3.0% | +0.2% | +6.1% | -0.6% | +35.0% |
| Mar 13 | Mizuho | Maintains | Outperform → Outperform | — | $17.04 | $17.47 | +2.5% | -3.8% | +1.6% | +1.1% | +1.9% | -3.0% |
| Mar 10 | Citigroup | Maintains | Sell → Sell | — | $17.64 | $17.63 | -0.1% | +0.1% | -0.5% | -3.1% | -3.8% | +1.6% |
| Mar 2 | HC Wainwright & Co. | Maintains | Sell → Sell | — | $16.76 | $16.28 | -2.9% | -2.6% | -2.8% | +1.4% | +0.9% | +3.0% |
| Feb 27 | Wells Fargo | Maintains | Overweight → Overweight | — | $17.45 | $17.17 | -1.6% | -4.0% | -2.6% | -2.8% | +1.4% | +0.9% |
| Jan 27 | HC Wainwright & Co. | Maintains | Sell → Sell | — | $22.80 | $22.30 | -2.2% | -2.8% | -3.9% | -0.3% | -4.2% | +1.9% |
| Jan 23 | Wedbush | Maintains | Outperform → Outperform | — | $21.79 | $21.89 | +0.5% | -3.0% | +7.9% | -2.8% | -3.9% | -0.3% |
| Jan 14 | HC Wainwright & Co. | Maintains | Sell → Sell | — | $21.46 | $21.56 | +0.5% | +6.2% | -6.5% | -0.8% | -0.4% | +1.6% |
| Nov 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $16.20 | $16.59 | +2.4% | +15.2% | -5.5% | -0.1% | -2.0% | +4.1% |
| Nov 5 | Guggenheim | Maintains | Buy → Buy | — | $16.20 | $16.59 | +2.4% | +15.2% | -5.5% | -0.1% | -2.0% | +4.1% |
| Nov 5 | Mizuho | Upgrade | Neutral → Outperform | — | $16.20 | $16.59 | +2.4% | +15.2% | -5.5% | -0.1% | -2.0% | +4.1% |
| Nov 5 | Barclays | Maintains | Equal Weight → Equal Weight | — | $16.20 | $16.59 | +2.4% | +15.2% | -5.5% | -0.1% | -2.0% | +4.1% |
| Nov 4 | Baird | Maintains | Neutral → Neutral | — | $24.45 | $15.24 | -37.7% | -33.7% | +15.2% | -5.5% | -0.1% | -2.0% |
| Oct 30 | Piper Sandler | Maintains | Neutral → Neutral | — | $23.45 | $23.22 | -1.0% | -0.9% | +3.3% | +1.8% | -33.7% | +15.2% |
| Sep 22 | BMO Capital | Upgrade | Market Perform → Outperform | — | $17.43 | $18.50 | +6.1% | +7.0% | -3.9% | +1.8% | -3.0% | +3.6% |
| Sep 15 | Guggenheim | Maintains | Buy → Buy | — | $17.39 | $17.47 | +0.5% | +0.5% | +3.6% | -5.8% | +8.6% | -5.9% |
| Sep 9 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $17.60 | $17.72 | +0.7% | +0.2% | -2.4% | +4.0% | -2.9% | +0.5% |
| Aug 25 | HC Wainwright & Co. | Maintains | Sell → Sell | — | $20.22 | $20.27 | +0.2% | -10.7% | +1.1% | -1.0% | +1.5% | -0.8% |
| Aug 21 | BofA Securities | Maintains | Underperform → Underperform | — | $20.58 | $19.37 | -5.9% | -2.5% | +0.8% | -10.7% | +1.1% | -1.0% |
| Aug 20 | BofA Securities | Maintains | Underperform → Underperform | — | $20.18 | $20.17 | -0.0% | +2.0% | -2.5% | +0.8% | -10.7% | +1.1% |
| Aug 15 | Deutsche Bank | Maintains | Sell → Sell | — | $20.30 | $20.43 | +0.6% | +7.4% | -3.8% | -3.9% | +2.0% | -2.5% |
| Aug 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $16.26 | $18.25 | +12.2% | +10.5% | +1.5% | -1.6% | +4.8% | +8.5% |
| Aug 7 | Goldman Sachs | Maintains | Neutral → Neutral | — | $16.26 | $18.25 | +12.2% | +10.5% | +1.5% | -1.6% | +4.8% | +8.5% |
| Jul 30 | Barclays | Upgrade | Underweight → Equal Weight | — | $15.83 | $17.68 | +11.7% | +5.8% | -2.0% | -3.1% | +7.5% | -2.0% |
| Jul 29 | Needham | Maintains | Underperform → Underperform | — | $13.86 | $18.23 | +31.5% | +14.2% | +5.8% | -2.0% | -3.1% | +7.5% |
| Jul 29 | Oppenheimer | Upgrade | Perform → Outperform | — | $13.86 | $18.23 | +31.5% | +14.2% | +5.8% | -2.0% | -3.1% | +7.5% |
| Jul 29 | JP Morgan | Upgrade | Underweight → Neutral | — | $13.86 | $18.23 | +31.5% | +14.2% | +5.8% | -2.0% | -3.1% | +7.5% |
| Jul 29 | BMO Capital | Maintains | Market Perform → Market Perform | — | $13.86 | $18.23 | +31.5% | +14.2% | +5.8% | -2.0% | -3.1% | +7.5% |
| Jul 29 | Piper Sandler | Maintains | Neutral → Neutral | — | $13.86 | $18.23 | +31.5% | +14.2% | +5.8% | -2.0% | -3.1% | +7.5% |
| Jul 29 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $13.86 | $18.23 | +31.5% | +14.2% | +5.8% | -2.0% | -3.1% | +7.5% |
| Jul 29 | Barclays | Upgrade | Underweight → Equal Weight | — | $13.86 | $18.23 | +31.5% | +14.2% | +5.8% | -2.0% | -3.1% | +7.5% |
| Jul 28 | Needham | Maintains | Underperform → Underperform | — | $11.93 | $11.71 | -1.8% | +16.2% | +14.2% | +5.8% | -2.0% | -3.1% |
| Jul 27 | Barclays | Downgrade | Equal Weight → Underweight | — | — | — | — | — | — | — | — | — |
| Jul 25 | JP Morgan | Downgrade | Neutral → Underweight | — | $12.88 | $11.14 | -13.5% | -7.4% | +16.2% | +14.2% | +5.8% | -2.0% |
| Jul 25 | Deutsche Bank | Maintains | Sell → Sell | — | $12.88 | $11.14 | -13.5% | -7.4% | +16.2% | +14.2% | +5.8% | -2.0% |
| Jul 24 | Jefferies | Maintains | Buy → Buy | — | $13.32 | $12.78 | -4.1% | -3.3% | -7.4% | +16.2% | +14.2% | +5.8% |
| Jul 24 | Wells Fargo | Maintains | Overweight → Overweight | — | $13.32 | $12.78 | -4.1% | -3.3% | -7.4% | +16.2% | +14.2% | +5.8% |
| Jul 23 | BofA Securities | Downgrade | Neutral → Underperform | — | $13.62 | $13.44 | -1.3% | -2.2% | -3.3% | -7.4% | +16.2% | +14.2% |
| Jul 22 | Barclays | Downgrade | Overweight → Equal Weight | — | $13.32 | $12.45 | -6.5% | +2.3% | -2.2% | -3.3% | -7.4% | +16.2% |
| Jul 22 | Needham | Maintains | Underperform → Underperform | — | $13.32 | $12.45 | -6.5% | +2.3% | -2.2% | -3.3% | -7.4% | +16.2% |
| Jul 22 | Piper Sandler | Maintains | Neutral → Neutral | — | $13.32 | $12.45 | -6.5% | +2.3% | -2.2% | -3.3% | -7.4% | +16.2% |
| Jul 22 | BMO Capital | Maintains | Market Perform → Market Perform | — | $13.32 | $12.45 | -6.5% | +2.3% | -2.2% | -3.3% | -7.4% | +16.2% |
| Jul 21 | Leerink Swann | Downgrade | Outperform → Market Perform | — | $14.08 | $12.82 | -8.9% | -5.4% | +2.3% | -2.2% | -3.3% | -7.4% |
| Jul 21 | Mizuho | Downgrade | Outperform → Neutral | — | $14.08 | $12.82 | -8.9% | -5.4% | +2.3% | -2.2% | -3.3% | -7.4% |
| Jul 21 | Deutsche Bank | Downgrade | Hold → Sell | — | $14.08 | $12.82 | -8.9% | -5.4% | +2.3% | -2.2% | -3.3% | -7.4% |
| Jul 21 | JP Morgan | Maintains | Overweight → Overweight | — | $14.08 | $12.82 | -8.9% | -5.4% | +2.3% | -2.2% | -3.3% | -7.4% |
| Jul 21 | Piper Sandler | Maintains | Neutral → Neutral | — | $14.08 | $12.82 | -8.9% | -5.4% | +2.3% | -2.2% | -3.3% | -7.4% |
No insider trades available.
8-K
Unknown — 8-K Filing
A new executive compensation package signals leadership continuity, but the $540,000 salary and 40% bonus structure indicate moderate executive costs that shouldn't meaningfully impact shareholder value.
Apr 15
8-K · 5.02
!!! Very High
Sarepta Therapeutics,, Inc. -- 8-K 5.02: Executive Change
Sarepta Therapeutics initiated a CEO search following Douglas Ingram's departure, potentially signaling leadership transition uncertainty that could impact investor confidence in the gene therapy company's strategic direction.
Feb 25
8-K
Sarepta Therapeutics,, Inc. -- 8-K Filing
Sarepta Therapeutics reported its Q4 and full-year 2025 financial results, providing investors with updated revenue, profitability, and operational metrics for the precision genetic medicine company.
Feb 25
Data updated apr 27, 2026 2:51am
· Source: massive.com